FDA Approves Liraglutide for Adolescents With Obesity FDA Approves Liraglutide for Adolescents With Obesity
The new indication for liraglutide for weight loss in adolescents with obesity was welcomed as a milestone.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 11, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news
FDA approves weight management drug for patients aged 12 and older
The U.S. Food and Drug Administration has approved Saxenda (liraglutide) for chronic weight management among patients aged 12 and older who are obese. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 4, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news
FDA Approves Saxenda (liraglutide) for the Treatment of Obesity in Adolescents Aged 12-17
PLAINSBORO, N.J., Dec. 4, 2020 /PRNewswire/ -- Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) approved an updated label for Saxenda® (liraglutide) injection 3 mg for use in the treatment of... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 4, 2020 Category: Drugs & Pharmacology Source Type: news
Liraglutide overdose: a case report and an updated review - Nafisah SB, Almatrafi D, Al-Mulhim K.
Little is known about liraglutide overdose and in particular its association with hypoglycemia. The aim of this study was to report on an accidental case of liraglutide overdose and to review similar cases in the literature. Here, we report a case of a you... (Source: SafetyLit)
Source: SafetyLit - August 13, 2020 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
Liraglutide Plus Exercise Helps Maintain Weight Loss: S-LITE Liraglutide Plus Exercise Helps Maintain Weight Loss: S-LITE
' It is not enough to go on a diet and lose weight, ' the researchers stress. Patients need ' active treatment after the weight loss in order to maintain [this lower] weight and health benefits. 'Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - June 29, 2020 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
ENDO: Liraglutide May Benefit Adolescents With Obesity
WEDNESDAY, April 1, 2020 -- Liraglutide plus lifestyle therapy results in a significantly greater reduction in body mass index (BMI) standard-deviation score than placebo among adolescents with obesity, according to a study published online March 31... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 1, 2020 Category: Pharmaceuticals Source Type: news
Newly discovered brain response to obesity drug may inform future treatments
The U.S. Food and Drug Administration-approved drug liraglutide has been shown to help obese patients lose weight by suppressing their appetite. However, where and how the drug acts in the brain was not fully understood, until now. A new preclinical study from the Perelman School of Medicine at the University of Pennsylvania, published in Science Translational Medicine today, shows how (Source: World Pharma News)
Source: World Pharma News - March 4, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Liraglutide Enhances Weight Loss With Intensive Behavioral Therapy
TUESDAY, Feb. 25, 2020 -- Intensive behavioral therapy (IBT) produces clinically meaningful weight loss in a primary care setting, which is enhanced in combination with liraglutide, according to a study published online Feb. 24 in Obesity.
Thomas A.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 25, 2020 Category: Pharmaceuticals Source Type: news
Intensive behavioral therapy and liraglutide 3.0 mg show positive results for weight loss
(The Obesity Society) Intensive behavioral therapy (IBT) combined with liraglutide 3.0 mg (Saxenda) can produce clinically-meaningful weight loss in patients who receive the treatment in predominantly primary care settings, according to a study published online in Obesity, the flagship journal of The Obesity Society. The study is the first multi-site evaluation of the efficacy of IBT based on a treatment visit schedule covered by the Centers for Medicare and Medicaid Services (CMS). (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - February 24, 2020 Category: International Medicine & Public Health Source Type: news
UK Watchdog Turns Down Liraglutide (Saxenda) for Obesity UK Watchdog Turns Down Liraglutide (Saxenda) for Obesity
UK NICE cites"highly uncertain" cost-effectiveness estimates for liraglutide (Saxenda) for obesity and questions the appropriateness of a subgroup analysis of the SCALE trial in a draft ruling.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - January 30, 2020 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Could Liraglutide Stall the Onset of Type 2 Diabetes in Kids? Could Liraglutide Stall the Onset of Type 2 Diabetes in Kids?
Results promising for the GLP-1 agonist in the treatment of children and adolescents with type 2 diabetes.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - December 16, 2019 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Liraglutide Ups Risk for Gallbladder, Biliary Tract Events
MONDAY, Aug. 26, 2019 -- There is an increased risk for gallbladder- or biliary tract-related events among patients with type 2 diabetes taking liraglutide versus placebo, according to a study published online Aug. 9 in Diabetes Care.
Michael A.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 26, 2019 Category: Pharmaceuticals Source Type: news
Gallbladder, Biliary Tract Events Increased With Liraglutide Gallbladder, Biliary Tract Events Increased With Liraglutide
Post-hoc analysis from the LEADER trial explores the relevant factors and potential mechanisms.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - August 20, 2019 Category: Internal Medicine Tags: Diabetes & Endocrinology News Source Type: news
New ADA Update: Liraglutide for Youth and Technology Issues New ADA Update: Liraglutide for Youth and Technology Issues
Liraglutide for youth, dulaglutide cardiovascular outcomes data, and ' time-in-range ' guidelines inform the latest Living Standards updates.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 2, 2019 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news
EU approves type 2 diabetes drug for children
The Committee for Medicinal Products for Human Use of the European Medicines Agency has approved the GLP-1 agonist, liraglutide, for the treatment of children and adolescents with type 2 diabetes.Medscape (Source: Society for Endocrinology)
Source: Society for Endocrinology - July 4, 2019 Category: Endocrinology Source Type: news
